Intervention not reported
All‐cause mortality · malaria in infants
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
- Risk ratio 0.17 [0.01, 4.06]1 study · 147 participantsLow
Findings
What do systematic reviews say?
23 questions · 24 findings · 14 reviews · Infectious Diseases
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 25%Low 10 · 41.7%Moderate 7 · 29.2%High 1 · 4.2%
Intervention not reported
All‐cause mortality · malaria in infants
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
- Risk ratio 0.83 [0.36, 1.89]1 study · 676 participantsModerate
Intervention not reported
All‐cause mortality · children under 12 months of age
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
- Risk ratio 0.93 [0.74, 1.15]9 studies · 14588 participantsModerate
Intervention not reported
All‐cause mortality · malaria in infants
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
- Risk ratio 1.21 [0.58, 2.55]1 study · 684 participantsModerate
Intervention not reported
All‐cause mortality · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
- Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes onlyRR 2.22 [0.49, 10.11]1 study · 394 participantsLow
Antifungal prophylaxis vs no antifungal prophylaxis
All‐cause mortality · HIV‐positive people
Antifungal prophylaxis showed no clear difference in all‐cause mortality compared with no antifungal prophylaxis (low certainty).
1 finding from 1 review
- Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people 2018 · Cochrane Headline outcomes onlyRR 1.07 [0.8, 1.43]6 studies · 3220 participantsLow
Intervention not reported
All‐cause mortality · HIV‐positive adults
The intervention showed no clear difference in all‐cause mortality (high certainty).
1 finding from 1 review
- Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults 2017 · Cochrane Headline outcomes onlyRR 0.97 [0.8, 1.17]6 studies · 6565 participantsHigh
Oral iron with antimalarial prophylaxis vs placebo or no treatment
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
- RR 1.05 [0.52, 2.11]728 participantsLow
Vitamin D vs control
All‐cause mortality · children under 5 years of age
1 finding from 1 review
- Vitamin D supplementation for preventing infections in children under five years of age 2016 · Cochrane Headline outcomes onlyno estimate extracted1 study · 3046 participantsLow
Intervention not reported
All‐cause mortality · patients with managing pulmonary tuberculosis
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
- Adjunctive steroid therapy for managing pulmonary tuberculosis 2014 · Cochrane Headline outcomes onlyRR 0.77 [0.51, 1.15]18 studies · 3815 participantsLow
Intervention not reported
Mortality All‐cause death · Pregnant women (parity 0‐1)
It is very uncertain whether the intervention changes mortality All‐cause death (very low certainty).
1 finding from 1 review
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment 2014 · Cochrane Headline outcomes onlyRR 1.15 [0.44, 3.06]3 studies · 2097 participantsVery low
Intervention not reported
Mortality All‐cause death · Pregnant women (parity 2+)
It is very uncertain whether the intervention changes mortality All‐cause death (very low certainty).
1 finding from 1 review
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment 2014 · Cochrane Headline outcomes onlyRR 1.47 [0.42, 5.21]1 study · 2239 participantsVery low
Intervention not reported
Mortality All‐cause death · Pregnant women (all parities)
The intervention showed no clear difference in mortality All‐cause death (low certainty).
1 finding from 1 review
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment 2014 · Cochrane Headline outcomes onlyRR 0.84 [0.25, 2.74]4 studies · 6026 participantsLow
Intervention not reported
Mortality All‐cause death · Pregnant women (parity 0‐1)
It is very uncertain whether the intervention changes mortality All‐cause death (very low certainty).
1 finding from 1 review
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment 2014 · Cochrane Headline outcomes onlyRR 1.15 [0.44, 3.06]2 studies · 2097 participantsVery low
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review
- Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 2023 · Cochrane Headline outcomes onlyRR 0.04 [0, 0.68]1 study · 2224 participantsLow
Intervention not reported
All‐cause mortality at day 28 · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
- Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 2023 · Cochrane Headline outcomes onlyRR 0.63 [0.21, 1.86]1 study · 264 participantsVery low
Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
- RR 0.6 [0.14, 2.51]3 studies · 230 participantsVery low
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
- RR 0.77 [0.47, 1.25]6 studies · 2860 participantsModerate
Early ART vs delayed ART initiation
All‐cause mortality at 6 to 12 months · HIV‐positive people with cryptococcal meningitis
Early ART may leads to higher all‐cause mortality at 6 to 12 months compared with delayed ART initiation (low certainty).
1 finding from 1 review
- Early versus delayed antiretroviral treatment in HIV‐positive people with cryptococcal meningitis 2018 · Cochrane Headline outcomes onlyRR 1.42 [1.02, 1.97]4 studies · 294 participantsLow
Impact of Xpert MTB/RIF vs smear microscopy
All‐cause mortality among participants · people being investigated for tuberculosis (TB)
Impact of Xpert MTB/RIF showed no clear difference in all‐cause mortality among participants compared with smear microscopy (moderate certainty).
1 finding from 1 review
- Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis 2021 · Cochrane Headline outcomes onlyRR 0.89 [0.75, 1.05]5 studies · 9932 participantsModerate